

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this supplemental notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this supplemental notice.



**YiChang HEC ChangJiang Pharmaceutical Co., Ltd.**

**宜昌東陽光長江藥業股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 01558)**

## **SUPPLEMENTAL NOTICE OF 2023 THIRD EXTRAORDINARY GENERAL MEETING**

Reference is made to the notice of YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (the “**Company**”) dated 1 December 2023 (the “**Notice**”) for the 2023 third extraordinary general meeting of the Company (the “**EGM**”), which sets out the time and venue of the EGM and contains the resolutions to be considered and approved by the shareholders of the Company at the EGM (the “**Original Resolutions**”).

**SUPPLEMENTAL NOTICE IS HEREBY GIVEN** that the EGM will be held as originally scheduled at Conference Room, 4/F, Administration Building, Dongyangguang Scientific Park, No. 368 Zhen An Zhong Road, Chang’an County, Dongguan, Guangdong Province, the PRC at 10:00 a.m. on Wednesday, 27 December 2023 to consider and, if thought fit, to approve in addition to the Original Resolutions, the following resolutions (the “**New Resolutions**”). The New Resolutions were submitted to the EGM by Sunshine Lake Pharma Co., Ltd.\* (廣東東陽光藥業股份有限公司) and its wholly-owned subsidiary, HEC (Hong Kong) Sales Co., Limited (holding in aggregate approximately 51.41% of the issued shares of the Company) in compliance with the laws and the articles of association of the Company. Save as mentioned herein, all information and contents set out in the Notice remain unchanged. Shareholders and potential investors are advised to refer to the circular of the Company dated 1 December 2023 for further details in relation to the Framework Agreement. Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the supplemental circular of the Company dated 8 December 2023 (the “**Circular**”).

### **ORDINARY RESOLUTIONS**

3. “**THAT**:

- (i) the revised annual cap for the Energy Purchase Framework Agreement in the amount of RMB51,340,000 for the year ending 31 December 2023 (the “**Revised Annual Cap for the Energy Purchase Framework Agreement**”), and the transactions contemplated thereunder be and are hereby approved; and

(ii) any one Director be and is hereby authorised for and on behalf of the Company to execute all such other documents, instruments and agreements and to take all steps necessary and expedient to implement and/or give effect to and implement the Revised Annual Cap for the Energy Purchase Framework Agreement.”

4. “**THAT:**

(i) the revised annual caps for the APIs Purchase Agreement in the amounts of RMB58,946,300, RMB73,786,800 and RMB95,442,100 for the years ending 31 December 2023, 2024 and 2025, respectively (the “**Revised Annual Caps for the APIs Purchase Agreement**”), and the transactions contemplated thereunder be and are hereby approved; and

(ii) any one Director be and is hereby authorised for and on behalf of the Company to execute all such other documents, instruments and agreements and to take all steps necessary and expedient to implement and/or give effect to and implement the Revised Annual Caps for the APIs Purchase Agreement.”

5. “**THAT:**

(i) the revised annual caps for the Packaging and Production Materials Purchase Framework Agreement in the amounts of RMB48,600,000, RMB48,600,000 and RMB48,600,000 for the years ending 31 December 2023, 2024 and 2025, respectively (the “**Revised Annual Caps for the Packaging and Production Materials Purchase Framework Agreement**”), and the transactions contemplated thereunder be and are hereby approved; and

(ii) any one Director be and is hereby authorised for and on behalf of the Company to execute all such other documents, instruments and agreements and to take all steps necessary and expedient to implement and/or give effect to and implement the Revised Annual Caps for the Packaging and Production Materials Purchase Framework Agreement.”

6. “**THAT:**

(i) the revised annual cap for the Entrusted Processing Framework Agreement in the amounts of RMB105,805,500 for the year ending 31 December 2023 (the “**Revised Annual Cap for the Entrusted Processing Framework Agreement**”), and the transactions contemplated thereunder be and are hereby approved; and

(ii) any one Director be and is hereby authorised for and on behalf of the Company to execute all such other documents, instruments and agreements and to take all steps necessary and expedient to implement and/or give effect to and implement the Revised Annual Cap for the Entrusted Processing Framework Agreement.”

Yours faithfully  
On behalf of the Board  
**YiChang HEC ChangJiang Pharmaceutical Co., Ltd.**  
**TANG Xinfa**  
*Chairman*

Hubei, the PRC  
8 December 2023

*Notes:*

1. A supplemental form of proxy in respect of the ordinary resolutions numbered 3 to 6 mentioned above (the “**Supplemental Form of Proxy**”) is enclosed with the supplemental notice of the EGM of the Company dated 8 December 2023. The Supplemental Form of Proxy will not affect the validity of any form of proxy duly completed by you in respect of the resolutions set out in the Notice. If you have validly appointed a proxy to attend and act for you at the EGM but do not complete and deliver the Supplemental Form of Proxy, your proxy will be entitled to vote at his/her discretion on the resolutions set out in the supplemental notice of the EGM. If you do not duly complete and deliver the original form of proxy for the EGM but have duly completed and delivered the Supplemental Form of Proxy and validly appointed a proxy to attend and act for you at the EGM, your proxy will be entitled to vote at his/her discretion on the resolutions set out in the Notice.
2. Please refer to the Notice for details in respect of the other resolutions to be passed at the EGM, eligibility for attending the EGM, proxy, registration procedures and other relevant matters in relation to the EGM.

*As at the date of this supplemental notice, the board of directors of the Company consists of Mr. JIANG Juncai, Mr. WANG Danjin, Mr. LI Shuang and Mr. CHEN Hao as the executive directors; Mr. TANG Xinfu as a non-executive director; and Mr. TANG Jianxin, Ms. XIANG Ling and Mr. LI Xuechen as the independent non-executive directors.*